| Code | Description | Claims | Beneficiaries | Total Paid |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
5,802 |
5,055 |
$1.65M |
| 90834 |
Psychotherapy, 45 minutes with patient |
20,149 |
11,191 |
$1.19M |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
54,524 |
43,345 |
$1.18M |
| 90837 |
Psychotherapy, 53 minutes with patient |
8,793 |
4,688 |
$837K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,037 |
3,425 |
$737K |
| G0378 |
Hospital observation service, per hour |
1,240 |
1,054 |
$608K |
| 90832 |
Psychotherapy, 30 minutes with patient |
6,293 |
4,926 |
$321K |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
2,481 |
2,126 |
$244K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
4,819 |
1,634 |
$233K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,078 |
633 |
$214K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
1,476 |
1,034 |
$213K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
919 |
872 |
$165K |
| 80053 |
Comprehensive metabolic panel |
16,358 |
12,528 |
$164K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
1,829 |
1,201 |
$147K |
| 94010 |
|
529 |
465 |
$108K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
3,376 |
2,398 |
$86K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,519 |
1,419 |
$76K |
| 20610 |
|
1,443 |
1,191 |
$73K |
| 71046 |
Radiologic examination, chest; 2 views |
2,989 |
2,630 |
$55K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
1,284 |
1,128 |
$52K |
| 97161 |
|
478 |
412 |
$49K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
5,099 |
3,394 |
$43K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
16,203 |
12,375 |
$43K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
638 |
595 |
$42K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
72 |
66 |
$40K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
109 |
102 |
$40K |
| 71250 |
|
626 |
565 |
$35K |
| 92134 |
|
814 |
749 |
$34K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
1,113 |
1,005 |
$34K |
| 95811 |
|
25 |
12 |
$33K |
| 70450 |
Computed tomography, head or brain; without contrast material |
2,512 |
2,261 |
$32K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,785 |
1,429 |
$29K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
2,381 |
2,146 |
$20K |
| 71045 |
Radiologic examination, chest; single view |
1,931 |
1,742 |
$18K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
231 |
212 |
$17K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
4,136 |
2,499 |
$16K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
366 |
185 |
$16K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
146 |
118 |
$16K |
| 36415 |
Collection of venous blood by venipuncture |
8,092 |
6,505 |
$16K |
| 93922 |
|
66 |
63 |
$13K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
587 |
318 |
$13K |
| J3490 |
Unclassified drugs |
2,718 |
1,635 |
$12K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,460 |
1,275 |
$12K |
| 82962 |
|
6,184 |
2,969 |
$11K |
| 97162 |
|
80 |
65 |
$11K |
| 81001 |
|
4,480 |
3,827 |
$10K |
| 87631 |
|
504 |
438 |
$10K |
| 73560 |
|
401 |
359 |
$10K |
| 73030 |
|
149 |
120 |
$9K |
| 90715 |
|
287 |
229 |
$8K |
| 84484 |
|
6,538 |
4,242 |
$8K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
617 |
529 |
$7K |
| 90853 |
Group psychotherapy (other than of a multiple-family group) |
1,173 |
363 |
$7K |
| 94060 |
|
21 |
12 |
$7K |
| 87070 |
|
69 |
48 |
$7K |
| 85027 |
|
3,086 |
2,471 |
$6K |
| 86850 |
|
1,098 |
847 |
$5K |
| 93971 |
|
43 |
39 |
$5K |
| 73502 |
|
17 |
12 |
$4K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
2,900 |
2,786 |
$4K |
| J2704 |
Injection, propofol, 10 mg |
3,655 |
2,737 |
$4K |
| 80069 |
|
112 |
45 |
$4K |
| A9270 |
Non-covered item or service |
32,466 |
8,479 |
$4K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
4,449 |
3,357 |
$4K |
| 80061 |
Lipid panel |
1,498 |
1,451 |
$4K |
| G2067 |
Medication assisted treatment, methadone; weekly bundle including dispensing and/or administration, substance use counseling, individual and group therapy, and toxicology testing, if performed (provision of the services by a medicare-enrolled opioid treatment program) |
24 |
15 |
$3K |
| 85610 |
|
3,504 |
2,919 |
$3K |
| 73110 |
|
38 |
25 |
$3K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
1,528 |
1,356 |
$3K |
| 73630 |
|
125 |
106 |
$3K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
3,569 |
2,379 |
$3K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
627 |
223 |
$3K |
| 87077 |
|
105 |
78 |
$3K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
3,572 |
3,064 |
$3K |
| 86140 |
|
1,160 |
1,046 |
$3K |
| 82803 |
|
855 |
614 |
$2K |
| 90686 |
|
622 |
571 |
$2K |
| 73610 |
|
85 |
78 |
$2K |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
1,237 |
1,141 |
$2K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
48 |
41 |
$2K |
| 90677 |
|
29 |
29 |
$2K |
| 85018 |
|
138 |
115 |
$2K |
| 92557 |
|
12 |
12 |
$2K |
| 90662 |
|
637 |
587 |
$2K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
85 |
49 |
$1K |
| 97116 |
|
147 |
37 |
$1K |
| 94727 |
|
397 |
374 |
$1K |
| C1769 |
Guide wire |
213 |
206 |
$1K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
524 |
498 |
$1K |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
13 |
12 |
$1K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
648 |
463 |
$1K |
| 73130 |
|
32 |
28 |
$1K |
| 94729 |
|
628 |
599 |
$1K |
| 97165 |
|
37 |
37 |
$1K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
1,083 |
865 |
$1K |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
61 |
45 |
$1K |
| 92083 |
|
13 |
12 |
$999.60 |
| 83605 |
|
1,989 |
1,474 |
$927.53 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
413 |
342 |
$845.07 |
| 81002 |
|
260 |
181 |
$812.94 |
| 82728 |
|
151 |
143 |
$725.79 |
| J1644 |
Injection, heparin sodium, per 1000 units |
1,167 |
706 |
$720.33 |
| 83880 |
|
2,672 |
2,054 |
$677.94 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,173 |
905 |
$670.37 |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
49 |
24 |
$667.79 |
| 96375 |
Therapeutic injection; each additional sequential IV push |
33 |
25 |
$662.40 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
2,805 |
2,129 |
$626.67 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
2,541 |
2,028 |
$610.90 |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
1,016 |
945 |
$605.67 |
| J3535 |
Drug administered through a metered dose inhaler |
27 |
24 |
$489.38 |
| 86900 |
|
873 |
731 |
$481.10 |
| 83735 |
|
4,834 |
3,526 |
$437.42 |
| J1815 |
Injection, insulin, per 5 units |
340 |
154 |
$428.21 |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
14 |
14 |
$425.55 |
| 84439 |
|
702 |
628 |
$424.23 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
177 |
156 |
$408.19 |
| 84443 |
Thyroid stimulating hormone (TSH) |
2,434 |
2,293 |
$313.10 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
1,772 |
1,564 |
$295.64 |
| 83690 |
|
1,879 |
1,707 |
$294.82 |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
16 |
14 |
$273.66 |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
38 |
28 |
$247.12 |
| J1170 |
Injection, hydromorphone, up to 4 mg |
202 |
145 |
$198.15 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
606 |
451 |
$173.58 |
| 70486 |
|
13 |
12 |
$166.49 |
| 84703 |
|
96 |
89 |
$166.43 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
1,780 |
1,499 |
$160.51 |
| 84702 |
|
330 |
308 |
$156.82 |
| 86901 |
|
872 |
731 |
$151.76 |
| 82330 |
|
67 |
63 |
$141.15 |
| Q0163 |
Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen |
1,214 |
782 |
$129.58 |
| 85730 |
|
1,315 |
1,180 |
$127.83 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
126 |
94 |
$121.36 |
| 84132 |
|
1,239 |
1,151 |
$117.35 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
941 |
715 |
$101.57 |
| 82947 |
|
69 |
67 |
$96.76 |
| 85651 |
|
526 |
502 |
$94.88 |
| 82607 |
|
26 |
26 |
$93.48 |
| 82077 |
|
213 |
196 |
$88.66 |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
509 |
354 |
$84.21 |
| J2060 |
Injection, lorazepam, 2 mg |
109 |
70 |
$78.69 |
| 82043 |
|
228 |
227 |
$76.66 |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
110 |
94 |
$74.43 |
| 97535 |
Self-care/home management training, each 15 minutes |
18 |
12 |
$67.29 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
507 |
479 |
$64.27 |
| 82565 |
|
302 |
288 |
$60.39 |
| 82150 |
|
57 |
52 |
$56.78 |
| 83540 |
|
288 |
275 |
$38.49 |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
27 |
26 |
$38.29 |
| 84466 |
|
314 |
300 |
$31.87 |
| 81025 |
|
14 |
13 |
$28.17 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
74 |
58 |
$25.93 |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
25 |
24 |
$19.15 |
| J7050 |
Infusion, normal saline solution, 250 cc |
517 |
425 |
$5.14 |
| 84100 |
|
457 |
341 |
$4.07 |
| 84295 |
|
115 |
112 |
$3.71 |
| 82435 |
|
25 |
25 |
$3.71 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
14 |
12 |
$0.65 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
252 |
230 |
$0.47 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
350 |
317 |
$0.04 |
| G8990 |
Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals |
15 |
12 |
$0.01 |
| G8991 |
Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
15 |
12 |
$0.01 |
| G1012 |
Clinical decision support mechanism agilemd, as defined by the medicare appropriate use criteria program |
2,385 |
1,549 |
$0.00 |
| 82948 |
|
179 |
108 |
$0.00 |
| 83970 |
|
69 |
67 |
$0.00 |
| 90656 |
|
35 |
35 |
$0.00 |
| 85652 |
|
384 |
361 |
$0.00 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
697 |
604 |
$0.00 |
| 85379 |
|
216 |
212 |
$0.00 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
13 |
12 |
$0.00 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
28 |
28 |
$0.00 |
| 96415 |
|
27 |
25 |
$0.00 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
35 |
29 |
$0.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
22 |
22 |
$0.00 |